secretin human (chirhostim) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Secretin is a hormone that regulates water homeostasis throughout the body and influences the environment of the duodenum by regulating secretions in the stomach, pancreas, and liver. It is a peptide hormone produced in the S cells of the duodenum, which are located in the intestinal glands. In humans, the secretin peptide is encoded by the SCT gene.   Wikipedia

Chemistry

  • SMILES: CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N
  • InChIKey: OWMZNFCDEHGFEP-NFBCVYDUSA-N
  • Mol. Mass: 3039.46
  • ALogP: Missing data
  • ChEMBL Molecules:
    secretin synthetic human  
    secretin synthetic porcine  
    secretin  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

chirhostim | human secretin | secreflo | secretin | secretin-ferring | secretin human | secretin (human) | secretin-kabi | secretin (swine), 15-l-glutamic acid-16-glycine- | secretin synthetic human | secretin synthetic porcine | synthetic human secretin

Organizations (26)

Research & Development (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (3)


 

Exocrine Pancreatic Insufficiency (approved 2004)

Gastrinoma (approved 2004)

Pancreatic Diseases (approved 2002)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Abdominal Pain (Phase 3)

Autistic Disorder (Phase 3)

Cholangiopancreatography, Endoscopic Retrograde (Phase 4)

Dyspepsia (Phase 1/Phase 2)

Healthy Volunteers (Phase 1/Phase 2)

Irritable Bowel Syndrome (Phase 3)

Neoplasms (Phase 1)

Obesity (Phase 2/Phase 3)

Obsessive Behavior (Phase 2)

Pancreatic Diseases (Phase 3)

Pancreatic Neoplasms (Phase 1/Phase 2)

Pancreatitis (Phase 3)

Pancreatitis, Chronic (Phase 1/Phase 2)

Schizophrenia (Phase 2)

Sphincter of Oddi Dysfunction (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial Organizations: 25

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue